Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents

Hepatitis C virus (HCV) genotype 3 is responsible for 30.1% of chronic hepatitis C infection cases worldwide. In the era of direct-acting antivirals, these patients have become one of the most challenging to treat, due to fewer effective drug options, higher risk of developing cirrhosis and hepatoce...

Descripción completa

Detalles Bibliográficos
Autores principales: Zanaga, L.P., Miotto, N., Mendes, L.C., Stucchi, R.S.B., Vigani, A.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Divulgação Científica 2016
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089232/
https://www.ncbi.nlm.nih.gov/pubmed/27783808
http://dx.doi.org/10.1590/1414-431X20165504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5089232/
https://www.ncbi.nlm.nih.gov/pubmed/27783808
http://dx.doi.org/10.1590/1414-431X20165504

Ejemplares similares